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Introduction
In July, 2013, WHO issued consolidated guidelines for 
the use of antiretroviral drugs for the treatment and 
prevention of HIV infection.1 These guidelines 
recommended antiretroviral therapy for all HIV-positive 
adults whose CD4 count has fallen to 500 cells per μL or 
less, with treatment to be given irrespective of CD4 cell 
count for pregnant women, HIV-serodiscordant couples, 
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Summary
Background New WHO guidelines recommend initiation of antiretroviral therapy for HIV-positive adults with 
CD4 counts of 500 cells per μL or less, a higher threshold than was previously recommended. Country decision 
makers have to decide whether to further expand eligibility for antiretroviral therapy accordingly. We aimed to assess 
the potential health beneﬁ ts, costs, and cost-eﬀ ectiveness of various eligibility criteria for adult antiretroviral therapy 
and expanded treatment coverage.
Methods We used several independent mathematical models in four settings—South Africa (generalised epidemic, 
moderate antiretroviral therapy coverage), Zambia (generalised epidemic, high antiretroviral therapy coverage), India 
(concentrated epidemic, moderate antiretroviral therapy coverage), and Vietnam (concentrated epidemic, low 
antiretroviral therapy coverage)—to assess the potential health beneﬁ ts, costs, and cost-eﬀ ectiveness of various 
eligibility criteria for adult antiretroviral therapy under scenarios of existing and expanded treatment coverage, with 
results projected over 20 years. Analyses assessed the extension of eligibility to include individuals with CD4 counts 
of 500 cells per μL or less, or all HIV-positive adults, compared with the previous (2010) recommendation of initiation 
with CD4 counts of 350 cells per μL or less. We assessed costs from a health-system perspective, and calculated the 
incremental cost (in US$) per disability-adjusted life-year (DALY) averted to compare competing strategies. Strategies 
were regarded very cost eﬀ ective if the cost per DALY averted was less than the country’s 2012 per-head gross domestic 
product (GDP; South Africa: $8040; Zambia: $1425; India: $1489; Vietnam: $1407) and cost eﬀ ective if the cost per 
DALY averted was less than three times the per-head GDP.
Findings In South Africa, the cost per DALY averted of extending eligibility for antiretroviral therapy to adult patients 
with CD4 counts of 500 cells per μL or less ranged from $237 to $1691 per DALY averted compared with 2010 guidelines. 
In Zambia, expansion of eligibility to adults with a CD4 count threshold of 500 cells per μL ranged from improving 
health outcomes while reducing costs (ie, dominating the previous guidelines) to $749 per DALY averted. In both 
countries results were similar for expansion of eligibility to all HIV-positive adults, and when substantially expanded 
treatment coverage was assumed. Expansion of treatment coverage in the general population was also cost eﬀ ective. In 
India, the cost for extending eligibility to all HIV-positive adults ranged from $131 to $241 per DALY averted, and in 
Vietnam extending eligibility to patients with CD4 counts of 500 cells per μL or less cost $290 per DALY averted. In 
concentrated epidemics, expanded access for key populations was also cost eﬀ ective.
Interpretation Our estimates suggest that earlier eligibility for antiretroviral therapy is very cost eﬀ ective in low-
income and middle-income settings, although these estimates should be revisited when more data become available. 
Scaling up antiretroviral therapy through earlier eligibility and expanded coverage should be considered alongside 
other high-priority health interventions competing for health budgets.
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and individuals with active tuberculosis or hepatitis-B-
associated severe chronic liver disease. The decision to 
increase the threshold CD4 count from the 350 cells 
per μL recommended in 2010 was reached through a 
structured GRADE (Grading of Recommendations 
Assessment, Development and Evaluation) review 
process that assessed evidence for the clinical and 
epidemiological beneﬁ ts of earlier HIV initiation.2
Evidence that antiretroviral therapy reduces HIV 
infectiousness3,4 suggests that increasing the number of 
HIV-positive adults who are on treatment could have the 
potential to change the course of the epidemic in highly 
aﬀ ected regions.5,6 However, the resources necessary to 
implement these changes could be substantial.1 The 
recommendation for earlier initiation of antiretroviral 
therapy comes at a time when progress towards 
implementation of antiretroviral therapy is varied: at the 
end of 2012 only an estimated 61% of HIV-positive 
individuals with CD4 counts of 350 cells per μL or less in 
low-income and middle-income countries were receiving 
treatment.7 Even in settings where high coverage has 
been achieved, many patients start treatment late because 
of late HIV diagnosis and poor linkage to and retention 
in pre-antiretroviral care.8–10
In this context, decision makers have to consider 
whether resources should be devoted to implementing 
earlier eligibility, achieving high coverage and timely 
initiation of antiretroviral therapy for individuals with the 
greatest clinical need, or expanding other health pro-
grammes that might generate greater health gains. This 
decision should be based on assessment of the population-
level beneﬁ ts and costs of strategies to expand eligibility for 
antiretroviral therapy or increase coverage, accounting for 
the additional resources that would be needed. Whereas 
clinical trials can be used to assess the eﬀ ect of expanded 
eligibility criteria for individuals, mathematical models 
can be used to project the long-term eﬀ ects of policy 
decisions.11 In the past decade, mathematical models have 
been useful for understanding the potential epidemi-
ological eﬀ ects, public health beneﬁ ts, and costs of 
antiretroviral therapy in many populations.5,11–14
To better inform policy for antiretroviral therapy, we 
assembled 12 independently developed HIV epidemic 
models to generate estimates for the health beneﬁ ts, costs, 
and cost-eﬀ ectiveness of earlier eligibility for antiretroviral 
therapy using the most recent available evidence. We also 
assessed the cost-eﬀ ectiveness of increasing HIV testing 
and linkage to care to improve coverage of antiretroviral 
therapy. The use of several models allows for the 
identiﬁ cation of conclusions that can be robustly 
reproduced across models, which is crucial in view of the 
wide range of results seen in previous analyses.6 Because 
optimum strategies might be expected to diﬀ er in settings 
with diﬀ erent epidemic types, existing coverage of 
antiretroviral therapy, and income, we selected four 
countries with existing models of the eﬀ ect of antiretroviral 
therapy as case studies in an eﬀ ort to produce guidance 
applicable to a broad set of epidemic settings: South Africa 
(generalised epidemic, moderate antiretroviral therapy 
coverage), Zambia (generalised epidemic, high 
antiretroviral therapy coverage), India (concentrated 
epidemic, moderate antiretroviral therapy coverage), and 
Vietnam (concentrated epidemic, low antiretroviral 
therapy coverage).
Methods
Overview
We assessed the potential eﬀ ect of changes to adult 
eligibility guidelines for antiretroviral therapy and 
improvements in HIV testing and linkage to care in four 
low-income and middle-income countries. We calibrated 
existing, independently developed mathematical models 
to epidemic settings in South Africa (seven models), 
Zambia (four models), India (three models), and Vietnam 
(one model). All models were dynamic HIV transmission 
models that simulate HIV transmission in populations 
and HIV disease progression, and incorporate both the 
therapeutic beneﬁ ts of antiretroviral therapy for reducing 
HIV morbidity and mortality and the preventive beneﬁ ts 
associated with reduced HIV infectiousness (table 1).
We used model outputs that describe changes in the 
use of health care to estimate changes in costs borne by 
the HIV programme and the broader health system. We 
estimated the eﬀ ects of intervention strategies on HIV 
incidence, antiretroviral therapy costs and non-
antiretroviral therapy health-care costs, and disability-
adjusted life-years (DALYs) averted by comparing model 
projections of diﬀ erent antiretroviral therapy eligibility 
and access strategies over 20 years. We calculated 
incremental cost-eﬀ ectiveness ratios (ICERs; reported 
as cost per DALY averted) to compare alternative 
strategies.
Epidemiological modelling
The models represented three eligibility criteria by which 
antiretroviral therapy could be started for adult patients 
in care: HIV-positive adults with a CD4 count of 350 cells 
per μL or less (assumed to be the existing, baseline 
strategy); HIV-positive adults with a CD4 count 
of 500 cells per μL or less; and all HIV-positive adults. 
Each model simulated a baseline projection representing 
existing treatment coverage (ie, patterns of HIV testing, 
linkage to and retention in pre-antiretroviral care, and 
uptake of antiretroviral therapy), which we refer to as the 
status-quo access to HIV care.
All three eligibility criteria were simulated with the 
assumption of a continuation of status-quo access to HIV 
care—ie, patients started on antiretroviral therapy are 
those already being linked to HIV care programmes in 
accordance with existing patterns of access. Models also 
simulated each eligibility strategy with the assumption of 
substantial increases in routine HIV testing and linkage 
to care across the adult population, such that 80% of 
adults infected with HIV would be in care when they 
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became eligible for antiretroviral therapy. For concentrated-
epi demic settings (India and Vietnam), models examined 
increased HIV testing and linkage to care in speciﬁ c key 
populations (female sex workers, men who have sex with 
men, and injecting drug users), such that 80% of these 
populations had access to antiretroviral therapy, while 
access for the general population remained at the 
status quo.
Alternative strategies for antiretroviral therapy 
eligibility and coverage of HIV care were simulated for 
a 20 year period from the beginning of 2014 to the end 
of 2033. For strategies involving expanded access to HIV 
care, the simulated change in access was implemented 
gradually over 2 years from the beginning of 2014.
Estimation of costs and cost-eﬀ ectiveness
We assessed incremental costs of each strategy from a 
health-system perspective, using a common costing 
framework across all models. The costs included were: 
service delivery costs necessary to identify and link HIV-
positive individuals to care; service delivery costs for 
patients receiving antiretroviral therapy or pre-anti-
retroviral care; potential cost savings due to reduced use 
of health care in the wider health system as HIV-positive 
individuals start to receive care through the HIV 
programme; and costs associated with programmatic 
support and supply-chain management (table 2). All 
costs are in addition to the basic amount of spending 
needed to support the programme. Country-speciﬁ c unit 
cost accounted for diﬀ erences in prices between 
countries, and all costs are reported in 2012 US$. The 
upfront costs of infrastructure investments are spread 
over their useful lifetime. The costing framework and 
sources of cost estimates are described in the appendix 
(pp 9–14).
We summarised health beneﬁ ts as DALYs averted, 
which capture improvements in both survival and 
quality of life that result from the direct beneﬁ ts of 
antiretroviral therapy in extending life for HIV-positive 
individuals and from reduced numbers of HIV 
infections. Disability weights (table 3) were drawn from 
the Global Burden of Disease Study 2010,28 which 
assessed the value of life-years lived in diﬀ erent health 
states compared with full health.
We calculated ICERs as the incremental cost per DALY 
averted over 20 years by an intervention compared with a 
less eﬀ ective, less costly alternative. Costs and health 
beneﬁ ts were discounted by 3% per year.29 On the basis of 
WHO recommended benchmarks, an intervention was 
classiﬁ ed as very cost eﬀ ective if its ICER was less than 
the country’s per-head gross domestic product (GDP) 
in 2012 (South Africa $8040; Zambia $1425; India $1489; 
Vietnam $1407),30 and cost eﬀ ective if it was less than 
three times the per-head GDP.29
Setting Model 
type*
Age-
structured
Heterogeneous 
sexual risk in 
general population†
Key populations included 
in model‡
Notes§
Goals15 South Africa and Zambia D Yes Yes Female sex workers and men who 
have sex with men
Incorporates tuberculosis disease
STDSIM16 South Africa M Yes Yes Female sex workers ··
EMOD17 South Africa and Zambia M Yes Yes ·· ··
BBH18 South Africa D No No Female sex workers and men who 
have sex with men
··
PopART19 South Africa and Zambia D No Yes ·· Incorporates tuberculosis disease
Synthesis20 South Africa M Yes Yes ·· Includes WHO stage 4 HIV disease as a criteria for 
antiretroviral therapy
Menzies21 South Africa D No No ·· Incorporates tuberculosis disease; does not include 
threshold CD4 count of 500 cells per μL
Macha22 Zambia D No No ·· ··
Pruddell23 Bangalore, India D No NA Female sex workers and men who 
have sex with men
Does not include threshold CD4 count of 500 cells per μL
Mishra24 Belgaum, India¶ D No No Female sex workers Does not include threshold CD4 count of 500 cells per μL
IDU-Manipur26 Churachandpur, India D No NA Present and former injecting drug 
users
Incorporates hepatitis C disease; does not include 
threshold CD4 count of 500 cells per μL
Prevtool27 Vietnam D No No Female sex workers, men who have 
sex with men, and injecting drug users
··
*D=deterministic compartment model structure; M=individual-based microsimulation model. †All models for South Africa and Zambia simulate the entire adult population (age 15 years and older); the Mishra 
model for Belgaum simulates the general adult population (age 15 years and older) of the Belgaum municipality; the Pruddell model simulates only subpopulations of present and former female sex workers and 
their clients, and men who sex with men; the IDU-Manipur model simulates present and former male injecting drug users and their heterosexual partners; and the Prevtool model for Vietnam simulates the 
general adult population (ages 15–49 years). ‡Concentrated epidemic models (India and Vietnam) assess expanded testing and linkage to care among these populations. §All models simulate eligibility for 
antiretroviral therapy for adult patients with CD4 counts of 350 cells per μL or less, and eligibility for all HIV-positive adults. ¶The Mishra model was also used for a second baseline simulation in which the 
increases in condom usage and access to antiretroviral therapy for female sex workers that followed the implementation of the Avahan intervention programme25 had not occurred and access to antiretroviral 
therapy for HIV-positive individuals (including female sex workers) remained poor, resulting in higher HIV incidence.
 Table 1: Epidemiological models and simulated strategies
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Role of the funding source
Authors from WHO contributed to the design of the study, 
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of epidemiological models, conduct of the analyses, or 
interpretation of results. The Bill & Melinda Gates 
Foundation had no role in the design of the analysis, 
interpretation of the results, or the decision to submit for 
publication. The corresponding author had ﬁ nal respon-
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Results
We ﬁ rst examined whether it would be cost eﬀ ective to 
change antiretroviral therapy eligibility criteria for adults 
in generalised-epidemic settings (ie, South Africa and 
Zambia). In South Africa, the ICER for changing the 
CD4 count threshold from 350 cells per μL to 500 cells 
per μL ranged from $273 to $1691 per DALY averted 
over 20 years (results from six models; ﬁ gure 1). The cost 
per DALY averted for changing eligibility to all HIV-
positive adults compared with eligibility for those with 
CD4 counts of 350 cells per μL or less ranged from 
$438 to $3790 (seven models). In Zambia, the ICER for 
expanding eligibility to patients with CD4 counts 
of 500 cells per μL or less ranged from improving health 
outcomes while reducing costs (ie, dominating the 
previous guidelines) to $749 per DALY averted (four 
models). For expanding eligibility to all HIV-positive 
adults compared with eligibility for those with CD4 counts 
of 350 cells per μL or less, results ranged from dominating 
the previous guidelines to $790 per DALY (four models).
The lower cost-eﬀ ectiveness ratios in Zambia compared 
with South Africa are partly due to lower non-
antiretroviral costs in Zambia (table 2). For South Africa 
and Zambia, most models showed slightly higher costs 
per DALY averted for expanding antiretroviral therapy 
eligibility to all HIV-positive adults compared with 
expansion to those with CD4 counts of 500 cells per μL or 
less (ﬁ ve of six models for South Africa and two of four 
for Zambia). However, these models also showed that the 
expansion of eligibility from a CD4 threshold of 500 cells 
per μL to all HIV-positive adults was still either cost 
eﬀ ective or very cost eﬀ ective (ﬁ gure 1).
South Africa Zambia India Vietnam
Costs of ART provision
Antiretroviral drug cost (per person-year) $143 $141 $91 $105
Non-antiretroviral cost (per person-year) $422 $217 $128 $198
ART initiation for patients in pre-ART care (per initiation) $95 $49 $29 $45
ART initiation for patients not in pre-ART care (per initiation) $126 $65 $38 $59
Cost of pre-ART care (per person-year)
CD4 count >350 cells per μL $205 $127 $73 $145
CD4 count >200–350 cells per μL $238 $139 $81 $150
CD4 count ≤200 cells per μL $359 $185 $109 $169
Cost of HIV testing and linkage (per diagnostic test done)
General population $20 $10 $6 $9
Female sex workers, men who have sex with men, and injecting drug users $67 $34 $20 $31
Costs of health-care use
CD4 count >350 cells per μL, not in HIV care (per person-year) $13 $5 $3 $2
CD4 count >200–350 cells per μL, not in HIV care (per person-year) $46 $17 $11 $7
CD4 count ≤200 cells per μL, not in HIV care (per person-year) $167 $63 $39 $26
End-of-life care (per death) $160 $50 $34 $32
Tuberculosis treatment (per case treated) $364 $188 $110 $172
Supply-chain management and programmatic support (% mark-up)
Supply-chain management* 20% 20% 20% 20%
Programmatic support† 50% 50% 50% 50%
All costs are in 2012 US$. ART=antiretroviral therapy. *Mark-up assessed on the basis of antiretroviral drug costs. †Mark-up assessed on the basis of all costs apart from 
antiretroviral drugs.
Table 2: Unit costs
Disability 
weight
HIV-positive, CD4 count >350 cells per μL (untreated)* 0·053
HIV-positive, CD4 count >200–350 cells per μL (untreated) 0·221
HIV-positive, CD4 count ≤200 cell per μL (untreated) 0·547
HIV-positive, on antiretroviral therapy 0·053
Tuberculosis disease 0·331
Disability weights are based on reference 26. For individuals with comorbidity 
(eg, concurrent HIV and tuberculosis disease), disability weights were compounded 
multiplicatively. *HIV infection with a CD4 count of 350 cells per μL or greater was 
assumed to cause the same disability (0·053) as is incurred by individuals receiving 
antiretroviral therapy.
 Table 3: Disability weights by health state
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Repeating the analysis for generalised epidemics with 
an assumption of greatly expanded HIV testing and 
linkage to care generated similar cost-eﬀ ectiveness ratios 
(appendix pp 20–21). ICERs that compared costs and 
beneﬁ ts over a shorter time period were much greater 
than for the full 20 year period (appendix pp 20–21): for 
example, in South Africa, over 5 years the highest ICER 
for changing the CD4 count threshold from 350 cells 
per μL to 500 cells per μL was $11 646, compared with 
$1691 over a 20 year period (with the assumption of 
status-quo treatment coverage). This ﬁ nding is because 
the eﬀ ect of increased use of antiretroviral therapy in 
reducing HIV transmission tends to increase over time 
in the models (appendix p 18).
We next examined the cost-eﬀ ectiveness of changing the 
eligibility criteria in concentrated-epidemic settings. In 
Vietnam, where the HIV epidemic is driven by female sex 
workers, men who have sex with men, and injecting drug 
users, the ICER was $290 for changing the CD4 count 
threshold from 350 cells per μL to 500 cells per μL and 
$289 for extending eligibility to all HIV-positive adults. In 
Bangalore, India, where the epidemic is driven by female 
sex workers and men who have sex with men, the ICER 
associated with eligibility for all HIV-positive adults 
compared with eligibility for those with CD4 counts 
of 350 cells per μL or less was $131 per DALY averted. In 
Manipur, India, where HIV is mainly spread by unsafe 
drug injection, the ICER for extending eligibility to all 
HIV-positive adults was $197 compared with eligibility for 
those with CD4 counts of 350 cells per μL or less. All of 
these policy changes would be very cost eﬀ ective.
In Belgaum district in southern India, where the 
epidemic is mainly associated with female sex workers, 
the ICER for eligibility for all HIV-positive adults 
compared with eligibility for those with CD4 counts 
of 350 cells per μL or less was $198 per DALY averted. 
Belgaum has undergone substantial reductions in HIV 
incidence in the past decade, associated with targeted 
interventions that have increased condom use and access 
to HIV care and treatment among sex workers.25,31 In a 
simulated scenario in which this intervention programme 
did not exist, the ICER would be $241 per DALY averted. 
Thus, earlier eligibility for antiretroviral therapy would 
be very cost eﬀ ective in epidemic settings similar to 
Belgaum with or without such programmes.
Change in eligibility for initiation of antiretroviral 
therapy is only one way in which decision makers could 
respond to the new guidelines. They could instead invest 
in expanding access (ie, HIV testing and linkage to care) 
to improve treatment coverage for individuals in greatest 
need (with CD4 counts of 350 cells per μL or less), or they 
could simultaneously adopt earlier eligibility criteria and 
expand testing and linkage to care. We also used the 
model results to compare these alternatives.
The relative eﬀ ects of these competing approaches 
with respect to incidence reduction diﬀ ered between 
settings (ﬁ gure 2). In South Africa, where existing 
antiretroviral therapy coverage is moderate, expansion of 
eligibility to adults with CD4 counts of 500 cells per μL or 
less would avert only 5–12% of new infections 
over 20 years. By contrast, expansion of testing and 
linkage to care while maintaining the CD4 count 
threshold of 350 cells per μL would have a larger eﬀ ect 
across the models (6–28% of infections averted). 
Changing eligibility to all HIV-positive adults would 
avert 9–32% without expansions in testing and linkage, 
Figure 1: Incremental cost per DALY averted for expanding eligibility criteria for antiretroviral therapy, by country and model
Results calculated over 20 years, with all costs and health beneﬁ ts discounted at 3% per year. All costs are in 2012 US$. Values below the upper dashed line (three-
times per-head gross domestic product [GDP]) are deﬁ ned as cost eﬀ ective; those below the lower dashed line (per-head GDP) are deﬁ ned as very cost eﬀ ective. The 
Menzies model (South Africa) and all models for India simulated only expanding eligibility to all HIV-positive adults. For the Goals model in Zambia, the estimated 
incremental cost-eﬀ ectiveness ratio (cost per disability-adjusted life-year [DALY] averted) is negative because over 20 years the strategy produces health beneﬁ ts and 
is estimated to be cost-saving because of the reduced treatment and care burden, including savings due to averted cost of tuberculosis treatment. *Indicates that 
eligibility for patients with CD4 counts of 500 cells per μL or less is dominated by the other strategy (ie, produces fewer health beneﬁ ts at higher cost).
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or 19–60% with such expansions. This relation is reversed 
in Zambia, which has higher coverage of antiretroviral 
therapy than South Africa: in all models, expansion of 
eligibility to all HIV-positive adults (21–40% infections 
averted) averted more infections than expansion of 
testing and linkage to care while maintaining the 
CD4 count threshold of 350 cells per μL (8–17%).
In both South Africa and Zambia, the additional costs 
of strategies that expand testing and linkage to care are 
much higher than the costs of strategies that only 
change eligibility (ﬁ gure 3). Earlier initiation of 
antiretroviral therapy for people who are already 
attending the clinic has a fairly low incremental cost 
because the cost of the additional years of antiretroviral 
Figure 2: Projected annual HIV incidence per 100 person-years for diﬀ erent stategies of antiretroviral therapy eligibility and access to HIV care, by country 
and model
In the generalised-epidemic settings (South Africa and Zambia), expanded access refers to expanded testing and linkage to care for the general population. In 
concentrated-epidemic settings (India and Vietnam), expanded access refers to expanded testing and linkage to care for all high-risk groups (female sex workers, men who 
have sex with men, and injecting drug users).
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therapy are partly oﬀ set by savings in pre-antiretroviral 
monitoring and other averted health-care costs. By 
contrast, strategies that expand testing and linkage to 
care require additional expenditure for HIV testing, pre-
antiretroviral monitoring, and antiretroviral therapy for 
patients diagnosed through expanded testing.
If the objective is to maximise the health returns per 
dollar spent, as an initial step of programme expansion, 
countries could prioritise the strategy that has the lowest 
cost per DALY averted (ﬁ gure 4). All models for Zambia 
suggest that expanding eligibility has the lowest cost per 
DALY averted. This result is robust to alternative 
assumptions about the relative costs of HIV testing and 
linkage, pre-antiretroviral monitoring, and provision of 
antiretroviral therapy (ﬁ gure 4). Four of seven models for 
South Africa suggest the same, but three models instead 
suggest that expanding testing and linkage to care would 
have the lowest cost per DALY averted. Overall, these 
results suggest that in settings with moderate to high 
coverage, expanding eligibility might be the preferred 
initial strategy. But expanding testing and linkage to care 
while maintaining the CD4 count eligibility threshold 
of 350 cells per μL might be a preferred initial strategy in 
settings with lower coverage, especially if testing and pre-
antiretroviral monitoring costs are low compared with 
the costs of providing antiretroviral therapy. Ultimately, 
both forms of expansion (ie, eligibility and testing and 
linkage) would be cost eﬀ ective relative to benchmarks—
if a country were to proceed by initially expanding in one 
way, it would still be cost eﬀ ective to extend services in 
the other way subsequently.
Whereas in generalised epidemics testing and linkage 
campaigns were assumed to be implemented in the 
general population, in concentrated epidemics it might 
be preferable to focus resources on speciﬁ c populations. 
In Belgaum, India, expanding eligibility to all HIV-
positive female sex workers, to all HIV-positive adults, or 
to all HIV-positive adults (with expanded HIV testing 
and linkage to care for female sex workers) would all be 
very cost eﬀ ective. The more extensive of these strategies 
would lead to greater reductions in new infections, albeit 
at a greater cost per DALY averted (table 4). However, 
intervention to expand testing and linkage to care for all 
adults in the general population resulted in an ICER of 
$5648 per DALY, which would not be cost eﬀ ective, 
although it could lead to the largest eﬀ ect on HIV 
incidence (53% of infections averted). Each of these 
interventions had lower ICERs in the simulated scenario 
that did not include the eﬀ ect of the prevention 
programmes in Belgaum (table 4).
For Vietnam, results were qualitatively similar to 
Belgaum (table 4); whereas expanding eligibility for the 
whole population and intervening to expand testing and 
linkage to care for female sex workers, men who have sex 
with men, and injecting drug users would be cost 
eﬀ ective, interventions to expand testing and linkage for 
the whole population would not (ICER $21 549).
Discussion
In all settings and across all models, extension of adult 
eligibility for antiretroviral therapy to people already in 
care with CD4 counts of 500 cells per μL or less, or to all 
Figure 3: Incremental costs over 20 years for diﬀ erent stategies of ART eligibility and access to HIV care 
compared with continuation of 2010 eligibility guidelines and status-quo access to care, by country
Costs are undiscounted, and reported in 2012 US$. Costs below the horizontal axis represent cost savings. In 
generalised-epidemic settings (South Africa and Zambia), expanded access (EA) refers to expanded testing and 
linkage to care for the general population. In concentrated-epidemic settings (India and Vietnam), expanded access 
refers to expanded testing and linkage to care for all high-risk groups (female sex workers [FSW], men who have sex 
with men [MSM], and injecting drug users [IDU]). For South Africa and Zambia, within each strategy each bar 
represents a model in the same sequence as the bars in ﬁ gure 1. The models for Belgaum and Vietnam also 
simulated expanded testing and linkage to care for the general adult population (table 4, appendix 
pp 17–19 and 22–23). ART=antiretroviral therapy. SQA=status-quo access. All=all HIV-positive adults.
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HIV-positive adults was very cost eﬀ ective over a 20 year 
period. These ﬁ ndings reﬂ ect the fairly low cost of 
providing additional years of antiretroviral therapy to 
people in care and the assumption that expanded access 
to antiretroviral therapy will reduce HIV transmission in 
the whole population, adding to the well established 
clinical beneﬁ ts of antiretroviral therapy in the reduction 
of morbidity and improvement of survival of HIV-
positive individuals (panel).
In the generalised-epidemic settings we examined, all 
models suggested that immediate implementation of 
the new WHO clinical recommendations for patients 
with CD4 counts of 500 cells per μL or less to start 
treatment would be cost eﬀ ective, even in settings where 
testing and linkage to care are still being increased to 
achieve universal access under the 2010 guidelines (in 
which patients are eligible if their CD4 cell count 
is 350 cells per μL or less). However, the models also 
show that, in settings where treatment coverage is 
incomplete, changing the eligibility criteria alone 
without an increase in access to HIV care, although cost 
eﬀ ective, would have a smaller eﬀ ect on health than 
would be achieved by increasing coverage of antiretroviral 
therapy for patients with a CD4 cell count of 350 cells 
per μL or less. Our modelling did not take into account 
cases in which resources are severely constrained, 
resulting in waiting lists of patients with low CD4 cell 
counts, or situations in which earlier eligibility would 
reduce access to antiretroviral therapy for patients with 
the greatest therapeutic need. The WHO guide-
lines1 recommend that, in such cases, treatment should 
be prioritised for patients with CD4 counts of 350 cells 
per μL or less.
In concentrated-epidemic settings, we estimated that 
extending eligibility for antiretroviral therapy to all HIV-
positive adults or those with CD4 counts of 500 cells 
per μL or less already in care would be very cost eﬀ ective. 
We also estimated that increases in HIV testing to 
achieve universal access to immediate antiretroviral 
therapy for members of speciﬁ c populations—namely 
Figure 4: Threshold analysis showing the strategies associated with the lowest cost per DALY averted for a speciﬁ c percentage change in the baseline cost 
assumed for pre-antiretroviral care and HIV diagnostic testing and linkage to care, by country and model
All strategies are compared with the baseline strategy (ie, continuation of the guidelines in which patients with CD4 counts of 350 cells per μL or less are eligible for 
antiretroviral therapy and status-quo access to HIV care).
–80
–40
0
40
80
–80
–40
0
40
80
–80
–40
0
40
Ch
an
ge
 in
 co
st
 o
f p
re
-A
RT
 ca
re
 (%
)
Change in diagnostic and linkage cost (%)
South Africa
–80 –40 0 40 80
Goals
–80 –40 0 40 80
STDSIM
–80 –40 0 40 80
EMOD
PopART Synthesis Menzies
BBH
Ch
an
ge
 in
 co
st
 o
f p
re
-A
RT
 ca
re
 (%
)
–80 –40 0 40 80
Ch
an
ge
 in
 co
st
 o
f p
re
-A
RT
 ca
re
 (%
)
Zambia
Goals EMOD Macha PopART
Change eligibility to CD4 count 
≤500 cells per μL
Change eligibility to all 
HIV-positive adults
Expand access, eligibility criteria 
unchanged
Change eligibility to CD4 count 
≤500 cells per μL and expand 
access
Change eligibility to all HIV-
positive adults and expand access
Articles
www.thelancet.com/lancetgh   Vol 2   January 2014 e31
female sex workers, men who have sex with men, and 
injecting drug users would be very cost eﬀ ective in India, 
and cost eﬀ ective in Vietnam. By contrast, widespread 
interventions to uniformly expand access to testing and 
treatment services for the general population were not 
estimated to be cost eﬀ ective in concentrated-epidemic 
settings. Other testing strategies not included in our 
analyses, such as provider-initiated testing, might be 
more eﬃ  cient at identifying HIV-positive adults, and 
could potentially be cost eﬀ ective in these settings.
Our results also suggest that investments in earlier 
eligibility for antiretroviral therapy should be regarded as 
a long-term investment in population health. Although 
upfront costs are high, the health beneﬁ ts generated by 
expanded eligibility increase over time (appendix p 18), 
such that the cost of averting ill health and premature 
death becomes progressively lower as cost and beneﬁ ts 
are assessed over longer time periods (appendix 
pp 20–23). However, by contrast with the conclusions of 
earlier analyses,5,12,32 our results did not show that the 
most eﬀ ective interventions will be cost-saving over 
a 20 year period.
This analysis brought together several independent 
models to examine the same policy question, and their 
collective ﬁ ndings were in general agreement about the 
cost-eﬀ ectiveness of earlier eligibility for antiretroviral 
therapy. The variation in some of the model results 
emphasises existing uncertainties and key directions for 
further data collection. Factors that contribute to this 
variation include diﬀ erent fundamental representations 
of the underlying epidemiology of HIV transmission and 
diﬀ erent expectations about future patterns of treatment 
uptake and eﬀ ectiveness. Several studies currently in 
progress or planned will provide further data about other 
key assumptions that directly underlie our conclusions—
particularly with respect to the therapeutic beneﬁ ts 
of earlier antiretroviral therapy (NCT00867048, 
NCT00495651), the scaling up of the individual prevention 
eﬃ  cacy of antiretroviral therapy to produce population-
level health beneﬁ ts33 and the eﬀ ect of antiretroviral 
therapy on risk behaviours (NCT01965470, NCT01900977, 
and NCT01509508), and the reduction of transmission 
risk through use of antiretroviral therapy by men who 
have sex with men34 and injecting drug users.35
Comparisons of model predictions with observational 
data can be useful. The epidemiological eﬀ ects of high 
antiretroviral therapy coverage in high-income countries 
have seemingly been mixed,36–41 but one observational 
Infections averted 
(%)
DALYs averted 
(thousands)
Additional cost 
(US$, millions)
ICER (US$)*
India
Belgaum model
Eligibility for female sex workers, status-quo access 13% 3·5 $0·2 $85
Eligibility for all HIV-positive adults, status-quo access 21% 9·0 $1·6 $268
Eligibility for all HIV-positive adults, prioritised access for female sex workers 29% 11·0 $2·3 $395
All HIV-positive adults, expanded access 52% 33·8 $123·9 $5648
Belgaum model (without condom intervention)
Eligibility for female sex workers, status-quo access 1% 0·9 $0·1 $73
Eligibility for all HIV-positive adults, status-quo access 1% 2·2 $0·5 ··†
Eligibility for all HIV-positive adults, prioritised access for female sex workers 41% 37·6 $4·0 $123
Eligibility for all HIV-positive adults, expanded access 66% 108·9 $138·7 $2054
Vietnam
Prevtool model
Eligibility for female sex workers, status-quo access 2% 41·5 $5·9 $161
Eligibility for men who have sex with men, status-quo access 5% 146·2 $37·1 ··†
Eligibility for injecting drug users, status-quo access 5% 149·1 $36·8 ··†
Eligibility for all adults with a CD4 count ≤500 cells per μL, status-quo access 4% 175·6 $47·5 ··†
Eligibility for all HIV-positive adults, status-quo access 12% 367·1 $96·4 $305
Eligibility for all adults with a CD4 count ≤500 cells per μL, prioritised access for female sex workers, 
men who have sex with men, and injecting drug users
30% 1497·5 $2442·6 ··†
Eligibility for all HIV-positive adults, prioritised access for female sex workers, men who have sex with 
men, and injecting drug users
52% 2082·5 $2485·7 $1586
Eligibility for all adults with a CD4 ≤500 cells per μL, expanded access 37% 2544·5 $25 692·5 ··†
Eligibility for all HIV-positive adults, expanded access 63% 3278·2 $25 725·4 $21 550
All costs are in 2012 US$. Proportion of infections averted, cumulative disability-adjusted life-years (DALYs) averted, and cumulative additional costs over 20 years are relative to eligibility for patients with CD4 
counts of 350 cells per μL or less and status-quo access to HIV care (undiscounted).*Incremental cost-eﬀ ectiveness (ICER) is the incremental cost per DALY averted over 20 years relative to the next most 
expensive strategy (excluding dominated strategies, which produce fewer health beneﬁ ts at higher cost); costs and estimated DALYs averted discounted at 3% per year. †Dominated strategy.
 Table 4: Health beneﬁ ts and costs of expanded eligibility or access to HIV care over 20 years, compared with 2010 eligibility guidelines and status-quo access to care
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study39 in rural South Africa showed that the risk of HIV 
infection was lower for individuals living in areas with 
higher coverage of antiretroviral therapy,42 and studies 
have not shown increases in sexual risk behaviour by 
people given early antiretroviral therapy43,44 or the general 
population.45 As in all scientiﬁ c endeavours, the con-
clusions of this analysis should be reassessed as new data 
become available.
The paucity of data for the costs of managing and 
supporting front-line services, the costs of scaling up and 
maintaining expanded testing programmes, and the ﬂ ow 
of patients through care services also add uncertainty to 
our estimates. Growing evidence suggests that unit costs 
will decrease as service provision sites expand and 
mature.46–48 However, how this eﬀ ect will translate to 
scale-up within a national programme context, which 
would probably involve expansion of existing sites as well 
as creation of new treatment sites and possibly novel care 
platforms, is unclear. Therefore, the experiences in 
countries that rapidly adopt earlier treatment and achieve 
high coverage should be used to provide better infor-
mation about the epidemiological and economic eﬀ ects 
that might be encountered by other countries.
We assessed cost-eﬀ ectiveness using a convention 
that approximates the social willingness to pay to 
achieve health gains with a country’s per-head GDP. 
Interventions shown to be cost eﬀ ective on the basis of this 
benchmark can be taken to be a reasonable investment, 
relative to a country’s present level of income.29 However, 
this suggestion does not mean that the present amount or 
distribution of health spending is optimum, or that other 
interventions (for HIV or other health issues) might not 
produce greater health gains per dollar spent. For example, 
analyses of medical male circumcision suggest that 
expansion of access to circumcision might have a lower 
ICER than expansion of access to antiretroviral 
therapy,18 and might even be cost-saving in the long 
term.49 National policy making will require explicit 
comparisons of alternative spending portfolios, which 
might include other interventions and a broader array of 
antiretroviral therapy and HIV-testing strategies. Similarly, 
countries will need to weigh aﬀ ordability and feasibility 
when considering large expansions in access to or 
eligibility for antiretroviral therapy. Implementing these 
strategies could require large, one-time investments in the 
years immediately after a policy change. In view of these 
costs and the uncertainties involved, some countries—
especially those with low coverage of antiretroviral therapy 
at present—could decide to take a gradual approach to 
changing the eligibility criteria.
For this study we adopted an analytical approach that 
assesses total health attainment (total DALYs averted) 
and is indiﬀ erent to how these health beneﬁ ts are 
distributed. For this reason, our results do not take into 
account other considerations for decisions makers, such 
as equity of treatment access. The conclusions of this 
analysis could therefore diﬀ er from those of a narrower 
analysis  focused  only on the health beneﬁ ts for people 
receiving antiretroviral therapy, especially since studies 
are still in progress to quantify the direct health beneﬁ ts 
of antiretroviral therapy at high CD4 cell counts.50 For the 
economic analysis we adopted a health-systems pers-
pective, which excludes some economic outcomes that 
might be valued by decision makers, such as reduced 
orphanhood, improved productivity, and survival of 
working-age adults. For all of these reasons, the general 
guidance from the four country case studies undertaken 
in this analysis should be regarded as an input into a 
decision-making process that weighs all locally relevant 
considerations, rather than a policy prescription.
The revised WHO recommendations1 have required 
decision makers to reconsider policies around anti-
retroviral therapy eligibility and treatment coverage, even 
while trials and demonstration projects are underway to 
quantify the consequences of expanded HIV treatment. 
As a result, uncertainties persist about key outcomes of 
these policies.51 However, informed by currently available 
epidemiological, biological, and economic information, 
the consensus ﬁ nding of this study is that extending 
eligibility for antiretroviral therapy to all adults with 
CD4 counts of 500 cells per μL or less, and potentially to 
all HIV-positive adults, would be cost eﬀ ective and 
Panel: Research in context
Systematic review
Recently WHO issued revised guidance for the use of antiretroviral therapy that includes 
the recommendation that HIV-positive adults should start receiving antiretroviral therapy 
when their CD4 count falls to 500 cells per μL or less.1 Countries now have to decide 
whether to adopt and implement these recommendations. Reductions in HIV 
infectiousness for people who start antiretroviral therapy earlier3 mean that both the 
individual therapeutic beneﬁ ts and prevention beneﬁ ts have to be taken into account 
when assessing the public health beneﬁ ts of earlier eligibility for antiretroviral therapy. 
Many mathematical models have been developed to examine the population-level health 
beneﬁ ts and costs of diﬀ erent strategies for antiretroviral therapy in low-income and 
middle-income country settings, and previous work has shown that results from diﬀ erent 
analyses can vary widely.6 This ﬁ nding suggests that taking into account results across 
diﬀ erent models and epidemic settings is essential for assessing the health eﬀ ect and 
cost-eﬀ ectiveness of earlier eligibility to inform policy decisions.
Interpretation
Expanding eligibility for antiretroviral therapy to adult patients with CD4 counts of 
500 cells per μL or less, or to all HIV-positive adults was cost eﬀ ective over 20 years in 
low-income and middle-income countries, relative to conventional WHO 
cost-eﬀ ectiveness benchmarks. Adoption of these recommendations should be 
considered alongside other high-priority health interventions in low-income and middle-
income countries. In generalised-epidemic settings, broad expansions of HIV testing and 
linkage to care to improve programme access was cost eﬀ ective and should also be 
considered by policy makers. In concentrated-epidemic settings, increased HIV testing 
and linkage to care for key populations at risk of transmitting HIV was very cost eﬀ ective 
and should be considered where possible. Widespread HIV testing programmes aimed at 
the entire adult population did not seem to be cost eﬀ ective in concentrated-epidemic 
settings, suggesting that health resources might be better allocated elsewhere.
Articles
www.thelancet.com/lancetgh   Vol 2   January 2014 e33
should be considered alongside other high-priority 
health interventions competing for health budgets in 
low-income and middle-income countries.
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